Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Orion announces phase III toremifene citrate data

Orion announces phase III toremifene citrate data

26th February 2008

Orion has announced the publication of results from a phase III clinical study of toremifene citrate 80mg, with the compound meeting primary and key endpoints in the trial.

The compound is being investigated in patients with advanced prostate cancer currently undergoing androgen deprivation therapy.

In the study, administration of the drug resulted in a 50 per cent reduction in the incidence of androgen deprivation induced osteoporosis related vertebral fractures while also meeting endpoints in gynecomastia, lipid profiles and bone mineral density.

“GTx licensed from Orion Corporation the rights to toremifene citrate for all indications worldwide, except breast cancer, outside the US,” the company reports.

GTx is a firm focused on the discovery, development and commercialisation of small molecule that treat medical conditions including cancer, muscle wasting, osteoporosis and bone loss through the selective targeting of hormone pathways.

Following this announcement, Orion reports that GTx plans to present the full trial data at an upcoming medical meeting and submit a new drug application to the regulatory authorities by this summer.

Earlier this month, Orion released its full year financial results for 2007, with the company reporting steady growth in net sales over the past 12 months.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.